ESTRO 2020 Abstract book

S625 ESTRO 2020

PO-1091 Quality of life and sexual function of men who have sex with other men treated for anal cancer G.P. Mauro 1 , K.G.M.D.C. Vasconcelos 2 , H.D.A. Carvalho 1 1 University of Sao Paulo, Radiology and Oncology, Sao Paulo, Brazil ; 2 Instituto do Cancer do Estado de Sao Paulo - ICESP, Radiotherapy, Sao Paulo, Brazil Purpose or Objective To assess quality of life (QoL) and sexual function (SxF) among men who have sex with other men (MSM) treated with radical chemorradiation for anal cancer. Material and Methods Prospective cohort of MSM who were treated for anal cancer in a single institution. For inclusion, patients had to be treated with concurrent chemoradiation (IMRT technique) with curative intent as by the ACTII randomized trial guideline. QoL and SxF were assessed by the questionnaires QLQ-C30, IIEF, and SF-36. The questionnaires were applied at diagnosis, after the end of the treatment, and 3, 6 and 12 months later on. Local control, systemic progression, colostomy-free, and overall survivals were measured from the date of diagnosis. Informed consent was obtained for inclusion. Results Patients were accrued between November 2015 and May 2019. Forty men were selected and 19, that accepted to participate in the study, were included. The most frequent causes of exclusion from the study were patient not MSM (11) and patients who were submitted to surgery or were not going to receive chemotherapy (5). Median age of the included patients was 59.3 years. The majority had advanced disease (14/73.7%) with a mean tumor size of 5.4 cm. Fifteen (78.9%) were HIV positive. The sexual inventory showed that most were homosexual cis-males (17/89.4%), single (11/57.9%), and monogamous (14/73.7%). No sexual intercourse over the month prior to treatment was stated by 12 patients (63.2%), and no pain during intercourse in the previous six months was reported by 13 (68.4%). Median follow-up was 19.8 months. Mean overall survival, systemic progression free survival, survival free of local relapse and colostomy-free survival were, respectively, 20.8, 19.8, 17.2 and 17.4 months. No median value was reached. Results of QLQ-C30 and SF-36 showed that QoL significantly worsened by the end of treatment and raised to maximum value by three months after treatment, followed by a continuous fall until the levels pre-treatment were reached again by 12 months after treatment. IIEF questionnaire showed that patients started treatment with moderate erectile dysfunction and reached normal level at 3 months after treatment, only to reach pre-treatment levels again by the end of first year after treatment. Intercourse frequency followed QoL measures, reaching a peak at 3 months and returning to pre-treatment levels by the end of first year of follow-up. Conclusion In a MSM population with anal canal cancer, QoL and SxF followed the same pattern up to one year after treatment. Most patients had their SxF compromised as shown by IIEF levels and intercourse frequency. Anal cancer and its’ treatment represent a burden to MSM regarding QoL and SxF. PO-1092 Clinical results of particle therapy in patients with postoperative recurrence of rectal cancer T. Waki 1 , T. Okimoto 2 , K. Terashima 2 , Y. Niwa 1 , D. Jin 1 , Y. Demizu 2 , K. Katsui 3 , S. Tokumaru 2 , S. Kanazawa 3 1 Tsuyama Chuo Hosptal, Radiology, Tsuyama-shi, Japan ; 2 Hyogo Ion Beam Medical Center, Radiology, Tatsuno-shi, Japan ; 3 Okayama University Hospital, Radiology, Okayama-shi, Japan Purpose or Objective To evaluate the outcome of particle therapy in patients with postoperative locoregional recurrence of rectal cancer at Hyogo Ion Beam Medical Center.

Conclusion This results supported a conservative approach in a subset of LARC pts who achieve MR or CR after nCRT. A standardized restaging with DRE, MRI and rectoscopy could increase the prediction of cCR. Furthermore a close FUP is needed because of the major risk of local recurrence and distance metastases. PO-1090 Quality of life among men who have sex with other men treated for anal cancer: Impact of HIV status G.P. Mauro 1 , K.G.M.D.C. Vasconcelos 2 , H.D.A. Carvalho 1 1 University of Sao Paulo, Radiology and Oncology, Sao Paulo, Brazil ; 2 Instituto do Cancer do Estado de Sao Paulo - icesp, Radiotherapy, Sao Paulo, Brazil Purpose or Objective In oncology studies, retrospective data usually identify MSM patients among people living with HIV (PLWHIV). Our aim is to describe the impact of HIV status on quality of life (QoL) and sexual function among MSM patients treated for anal cancer using validated QoL assessments questionnaires on PLWHIV population in a single institution cohort. Material and Methods Single institution prospective cohort of MSM who were treated for anal cancer and selected according to the HIV status. Patients were accrued between November 2015 and May 2019. All patients were treated with IMRT technology radiotherapy with concurrent chemotherapy as by the ACTII randomized trial guideline. Questionnaires were applied before treatment, at treatment end and then at 3, 6 and 12 months of follow-up. No patient had detectable virus load and all had CD4+ cell count high enough to receive chemotherapy. Results From 40 men that were assessed, 19 accepted to participate in the study and completed the requested questionnaire. From these, 15 PLWHIV are the subject of this analysis. Median age was 54.6 years and all patients had undetectable viral load and mean CD4+ count of 561 cells/mm 3 . With a median follow-up of 19.1 months, mean overall survival, systemic progression free survival, survival free of local relapse and colostomy-free survival were, respectively, 25.3, 24.0, 21.6 and 23.1 months. No median value was reached. Results of HIV/AIDS targeted QoL instrument showed that PLWHIV patients experienced drops on QoL sensitive to the instruments. The sexual function domain of this questionnaire showed the same pattern identified with IIEF questionnaire in the general cohort, showing that patients reach worse SF, reaching pre-treatment levels at six months after treatment. Conclusion Instruments direct aimed for PLWHIV can give better information on this group of patients. Our results show that patients treated for anal cancer that are MSM have a deterioration of their SF and that must be kept in mind so the best treatment can be given to this population, especially those that live with HIV.